NewsBenzinga허치메드의 경구용 Syk 억제제 소블레플레닙, 자가면역 용혈성 빈혈 치료제로 미국 FDA 희귀의약품 지정···초기 ITP에 이은 두 번째 지정, 승인 시 7년간 미국 시장 독점권 부여 허치메드의 경구용 Syk 억제제 소블레플레닙, 자가면역 용혈성 빈혈 치료제로 미국 FDA 희귀의약품 지정···초기 ITP에 이은 두 번째 지정, 승인 시 7년간 미국 시장 독점권 부여 Benzinga 2026.11.05 07:13 (GMT+0) Open on Benzinga Other news Needham Reiterates Buy on AppLovin, Maintains $475 Price Target Ecovyst Raises FY2026 Adj EPS Guidance from $0.58-$0.72 to $0.63-$0.77 vs $0.69 Est; Raises FY2026 Sales Guidance from $1.020B-$1.060B to $1.050B-$1.070B vs $1.035B Est BTIG Maintains Buy on Evolus, Raises Price Target to $15 Micron Technology Stock Slides Again Thursday: What's Going On? BTIG Maintains Buy on AppLovin, Raises Price Target to $450 Elizabeth Warren Says CVS Is Still Trying To ‘Rip People Off’ With Planned Breakup as Mark Cuban Says Split ‘Changes Nothing For Patients’
Ecovyst Raises FY2026 Adj EPS Guidance from $0.58-$0.72 to $0.63-$0.77 vs $0.69 Est; Raises FY2026 Sales Guidance from $1.020B-$1.060B to $1.050B-$1.070B vs $1.035B Est
Elizabeth Warren Says CVS Is Still Trying To ‘Rip People Off’ With Planned Breakup as Mark Cuban Says Split ‘Changes Nothing For Patients’
